Last reviewed · How we verify
JNJ-61393215
At a glance
| Generic name | JNJ-61393215 |
|---|---|
| Also known as | Orexin-1 |
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of JNJ-61393215 in the Treatment of Depression (PHASE2)
- A Study of JNJ-61393215 in Healthy Japanese Male Participants (PHASE1)
- A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants (PHASE1)
- Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-61393215 in Healthy Participants (PHASE1)
- A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants (PHASE1)
- A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ 61393215 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-61393215 CI brief — competitive landscape report
- JNJ-61393215 updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI